Can-Fite BioPharma’s (CANF) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Can-Fite BioPharma (NYSE:CANF) in a research report report published on Tuesday,Benzinga reports. The brokerage currently has a $10.00 price objective on the stock.

Several other analysts have also recently commented on the company. StockNews.com cut Can-Fite BioPharma from a “hold” rating to a “sell” rating in a research report on Friday, December 13th. HC Wainwright restated a “buy” rating and set a $18.00 price objective on shares of Can-Fite BioPharma in a research report on Tuesday, November 12th.

Can-Fite BioPharma Trading Up 10.2 %

NYSE CANF opened at $1.79 on Tuesday. Can-Fite BioPharma has a 1 year low of $1.29 and a 1 year high of $4.69. The company has a market cap of $6.34 million, a PE ratio of -1.00 and a beta of 1.32. The stock’s 50-day moving average price is $1.86 and its two-hundred day moving average price is $2.36.

Institutional Trading of Can-Fite BioPharma

An institutional investor recently raised its position in Can-Fite BioPharma stock. Armistice Capital LLC raised its holdings in Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 518,853 shares of the company’s stock after acquiring an additional 136,055 shares during the quarter. Armistice Capital LLC owned about 14.66% of Can-Fite BioPharma worth $1,339,000 at the end of the most recent quarter. Institutional investors and hedge funds own 21.00% of the company’s stock.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.